Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Study of Daratumumab for Microvascular Inflammation (MVI) in Kidney Transplant Recipients With or Without Donor-Specific Antibodies

NCT07274462 is registered in ClinicalTrials.gov with University Hospital, Martin as lead sponsor.

NCT NCT07274462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07274462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Study of Daratumumab for Microvascular Inflammation (MVI) in Kidney Transplant Recipients With or Without Donor-Specific Antibodies
Lead sponsor
University Hospital, Martin
Phase
Phase 4
Overall status
Active, not recruiting
Start date
November 1, 2025
Completion date
September 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microvascular inflammation - mvi in kindey transplant recipients